Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.
Company Details
- Employees
- 22
- Founded
- -
- Address
- 58, Pangyo-Ro 255 Beon-Gil, Bundang-Gu, Suite 303,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bridgebiorx.com
- HQ
- Seongnam-si, Gyeung-gi do
Bridge Biotherapeutics, Inc. Questions
Bridge Biotherapeutics, Inc.'s website is bridgebiorx.com
Bridge Biotherapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/bridgebiorx
Bridge Biotherapeutics, Inc. has
22 employees.
View email and phone details for 22
employees at Bridge Biotherapeutics, Inc..
Bridge Biotherapeutics, Inc.'s industry is
Biotechnology Research
Bridge Biotherapeutics, Inc.'s top competitors are
Vertex Pharmaceuticals,
Celltrion Inc,
Aribio,
Bridgebio,
Hitgen Inc.,
Bbot,
Classys,
Biomarin Pharmaceutical Inc.,
Hugel,
Alnylam Pharmaceuticals.
Bridge Biotherapeutics, Inc.'s categories are Biotechnology Research
Bridge Biotherapeutics, Inc.'s founding year is 2015
